A5005020542- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Biosimilars and Bioanalytical Methods
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Immunodeficiency and Autoimmune Disorders
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Cancer-related gene regulation
- HER2/EGFR in Cancer Research
- NF-κB Signaling Pathways
Rutgers, The State University of New Jersey
2015-2024
Rutgers Cancer Institute of New Jersey
2015-2024
Ipsen (United States)
2023
Stanford University
2019
Cancer Institute of Florida
2017-2018
Merck & Co., Inc., Rahway, NJ, USA (United States)
2010-2017
Johnson University
2013
MSD K.K. (Japan)
2013
Merck (Japan)
2011
Mary Crowley Cancer Research Center
2007
To study the effects of localized secretion cytokines on tumor progression, gene for human interleukin 2 (IL-2) was introduced via retroviral vectors into CMS-5 cells, a weakly immunogenic mouse fibrosarcoma cell line BALB/c origin. Secretion low levels IL-2 from cells abrogated their tumorigenicity and induced long-lasting protective immune response against challenge with tumorigenic dose parental cells. Co-injection IL-2-producing unmodified inhibited formation even when highly doses were...
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment ibrutinib plus venetoclax are reported. Patients received 3 cycles of lead-in then 12 (oral [420 mg/d]; oral [5-week ramp-up to 400 mg/d]). The primary endpoint was complete response (CR) rate. Hypothesis testing performed for without del(17p) prespecified analyses all treated...
This study explored the use of interleukin 2 (IL-2) and interferon gamma (IFN-gamma) gene-modified tumor cells as cellular vaccines for treatment bladder cancer. The mouse MBT-2 used is an excellent model human carcinogen-induced origin resembles cancer in its etiology histology, responds to a manner similar counterpart. Using retroviral vectors, IL-2 IFN-gamma genes were introduced expressed cells. tumor-forming capacity cytokine was significantly impaired, since no tumors formed mice...
Purpose: Rituximab has clinical activity in patients with chronic lymphocytic leukemia (CLL) and a variety of proposed mechanisms, including apoptosis, complement-dependent cell lysis (CDC), antibody-dependent cellular cytotoxicity (ADCC). Here we examine pretreatment biologic features that promote resistance to apoptosis CDC CLL correlate it outcome rituximab-based therapy. Patients Methods: Pretreatment samples from 21 treated on prospective, single-agent rituximab trial were examined for...
Dinaciclib, a small-molecule, cyclin-dependent kinase inhibitor, inhibits cell cycle progression and proliferation in various tumor lines vitro. We conducted an open-label, dose-escalation study to determine the safety, tolerability, bioactivity of dinaciclib adults with advanced malignancies. Dinaciclib was administered starting at dose 0.33 mg/m2, as 2-hour intravenous infusion once weekly for 3 weeks (on days 1, 8, 15 28-day cycle), maximum (MAD), dose-limiting toxicities (DLTs),...
Pancreatic cancer is one of the most lethal human malignancies, and potent therapeutic options are lacking. Inhibition cell cycle progression through pharmacological blockade cyclin-dependent kinases (CDK) has been suggested as a potential treatment option for cancers with deregulated control. Dinaciclib (SCH727965) novel small molecule multi-CDK inhibitor low nanomolar potency against CDK1, CDK2, CDK5 CDK9 that shown favorable toxicity efficacy in preliminary mouse experiments, well...
Patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an Fc-silenced, human, CD20×CD3 bispecific antibody that targets CD20-expressing cells via T-cell-mediated cytotoxicity independent of T-cell/major histocompatibility complex interaction. Phase I results in patients R/R B-NHL demonstrated odronextamab monotherapy could achieve deep and durable responses generally manageable safety profile (ELM-1;...
IFN-gamma genes were introduced through retroviral vectors into the high metastatic, low H-2Kb class I expressor, and poorly immunogenic 3LL-D122 clone. Two types of infectants isolated: secretors (128 to 256 IU/ml) non- or very (< 2 IU/ml). Both manifested expression MHC Ag. showed significant decrease in tumorigenicity metastatic growth, whereas nonsecretors retain more than parental D122 cells. However, both groups, when inoculated an irradiated form, induced similar levels CTL protected...
Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib acute leukemia both clinic vitro.Adults relapsed/refractory myeloid (n = 14) lymphoid 6) were treated 50 mg/m(2) given as 2-h infusion every 21 days.Most patients had dramatic but transient reduction circulating blasts; however, no remissions achieved on this schedule. The most common toxicities gastrointestinal,...
The treatment of patients with relapsed or refractory lymphoid neoplasms represents a significant clinical challenge. Here, we identify the pro-survival BCL-2 protein family member MCL-1 as resistance factor for inhibitor venetoclax in non-Hodgkin lymphoma (NHL) cell lines and primary NHL samples. Mechanistically, show that antibody-drug conjugate polatuzumab vedotin promotes degradation via ubiquitin/proteasome system. This targeted antagonism, when combined anti-CD20 antibodies...
Abstract IL‐2 gene was introduced through retroviral vectors into the highly malignant and poorly immunogenic 3LL‐D122 clone. Both high low D122‐11‐2 secretors showed elimination of tumorigenicity in syngeneic immune‐competent mice; however, nude mice only secretor reduced as compared with parental D 122 cells. Also, following intravenous inoculation, generation metastases, whereas were metastatic These results seem to indicate that levels secreted by tumor cells are sufficient activate T...
KRAS is activated by mutation in the vast majority of cases pancreatic cancer; unfortunately, therapeutic attempts to inhibit directly have been unsuccessful. Our previous studies showed that inhibition cyclin-dependent kinase 5 (CDK5) reduces cancer growth and progression, through blockage centrally important RAL effector pathway, downstream KRAS. In current study, effects combining CDK inhibitor dinaciclib (SCH727965; MK-7965) with pan-AKT MK-2206 were evaluated using orthotopic...
Dinaciclib is a potent inhibitor of cell cycle and transcriptional cyclin-dependent kinases. This Phase 1 study evaluated the safety, tolerability pharmacokinetics various dosing schedules dinaciclib in advanced solid tumour patients assessed pharmacodynamic preliminary anti-tumour activity. In part 1, were enrolled escalating cohorts 2-h infusions administered once every 3 weeks, utilising an accelerated titration design until recommended phase 2 dose (RP2D) was defined. 2, 8- 24-h...